For those who are looking into some of the notable gainers on Thursday, it might be a good move to perhaps take a closer look at the Seelos Therapeutics (NASDAQ:SEEL) stock. Yesterday, the stock was on the move and went up by as much as 8% after Seelos got bullish coverage from Yatin Suneja, an analyst at Guggenheim.
The analyst started covering the stock yesterday and gave it a buy rating. In addition to that, he set the target price of the Seelos stock at $8 a share. Hence, it is no surprise that investors piled on to the stock in a big way yesterday after the news broke.
The company is clinical stage biopharmaceutical operation that is involved in both the development as well as commercialisation of innovative therapies and technologies.
The company primarily works in the sphere of creating products meant for treating disorders related to respiration and the central nervous system. The bullish analysis from Suneja has naturally come as a major boost for the company and it is going to be interesting to see if the stock can continue to add to its gains over the course of the coming days. You could consider adding it to your watch list.
Market Reaction:
On Thursday, SEEL stock jumped 8% to $2.85 with more than 12.79 million shares, compared to its average volume of 5.03 million shares. The stock has moved within a range of $2.7500 – 3.1000 after opening the trade at $2.93. Over the past 52-week, the stock has been trading within a range of $0.5600 – 6.6000.
 Stock Turns Volatile: How To Trade Now?){kind=link}